Amount of qualified sufferers: CDEC reviewed the uncertainty in the quantity of patients with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some clients who're classified as having moderate or reasonable condition might have a severe bleeding phenotype, which https://eduardokkkif.shotblogs.com/everything-about-hemgenix-49742157